Replies to post #222644 on Biotech Values

[jbog]

Bottom line: RVNC is an even more compelling buy now than it was one month ago when I posted the analysis in #msg-144655043.

Earlier this year I decided there was no reason to own Revance because of the time it was going to take to file. I wasn't wrong to sit most of the year out.

I started nibbling about a month ago looking forward to today's announcement. I'm in the green but not by much.

Again I'm back to square one, why own the stock now. It seems they're taking a substantial amount of time to file their FDA paperwork, many other companies would have it filed within three months. While three months falls in their timeline, they are allowing themselves 7 months. Awful long in my view.

The next catalyst has to be whether they partner or not. If they partner I would think they'll have a hard time crawling back to $40, If they don't I can see expenses flying higher.

Best case for the stockholders right now would be for them to be acquired.

We'll see what happens.

[DewDiligence]

30-min interview with RVNC CEO, Dan Browne; questions are softballs, but it’s nevertheless a good listen for longs and prospective longs:

https://attendais.com/revance-ceo-browne-sheds-light-on-history-challenges-and-future-following-its-recent-clinical-news/

h/t DaveAu.

[DewDiligence]

Just added RVNC @$19.97-20.00:

https://twitter.com/DewDiligence/status/1074735221784875009

[DewDiligence]

RVNC has started phase-2 trials in upper-limb spasticity and plantar fasciitis—details in today’s PR:

https://finance.yahoo.com/news/revance-highlights-recent-regulatory-progress-130500861.html